Incyte Corporation

Money comes in mainly as direct payment for medicines once control of the product passes to the buyer, counted net of the rebates, discounts and similar deductions built into how drugs are actually paid for, together with royalty income on products licensed to other companies and with upfront and milestone payments from research and licensing agreements. Sales and gross profit have both risen through each of several recent years running, and the company has closed every one of its last several fiscal years with a profit rather than a loss.

Several independent measures of how efficiently assets and equity are turned into profit sit above where CompanyGraph places most of the industry, and they move together rather than just one at a time, which points away from the elevated returns being simply a function of borrowed capital. Read alongside the company's own description of relying on outside manufacturers for most physical production, this is consistent with a way of growing that adds newly approved drugs onto commercial and manufacturing infrastructure it mostly does not have to build itself, rather than growing by expanding owned physical capacity. This is how CompanyGraph makes sense of the pattern; it is not something the company itself describes as its growth mechanism.

The company relies on a small, sometimes singular, pool of outside suppliers for the raw materials and active ingredients behind its medicines, with the input for its largest product concentrated among suppliers based in China alongside one qualified alternative in Europe. It relies on outside contract manufacturers to turn those inputs into finished drug product for most of its portfolio, on outside collaborators and contract research organizations for parts of its development work, on a limited set of specialty pharmacies and wholesalers to reach the market, and on continued regulatory clearance to keep what is already approved on the market. By the company's own account, revenue itself also depends heavily on the continued performance of one flagship drug franchise.

Downstream, the medicines reach patients through a concentrated chain of specialty and retail pharmacies, specialty distributors and wholesalers, with hospital pharmacies, group purchasing organizations, public health bodies, nonprofit clinics and government health programs buying under separate contracted terms. In markets outside the United States, some of the company's drugs reach patients only because named partner companies hold the rights to sell them there. For a handful of its therapies, the company describes itself as the only approved option for the specific condition treated, meaning prescribers and patients facing that condition currently have no other approved product to turn to.

By its own account, what the company points to as protecting its position is its patents and pending patent applications, together with being first to market, or in a few cases the only approved option, for specific named conditions, backed by the regulatory approvals and specialized personnel needed to get and keep a drug on the market. CompanyGraph separately notes that the broader shape of business this company runs, earning only once a candidate clears a long approval process, is common: it places a great many other companies in that same category. What is distinctive here, if anything, sits in the specific patents and approvals attached to particular drugs rather than in the underlying business model, and how durable that protection is cannot be judged from here.

By its own account, the ceiling on how much the company can do is set by how much preclinical and clinical testing it can run at once, whether and when regulators clear each candidate, the availability of qualified scientific and clinical staff, and the capacity of the outside manufacturers and material sources it depends on. This matches the general pattern CompanyGraph associates with businesses that only earn from a product once it clears a long approval process: here the company's own stated limits line up with that gate being the central one, rather than describing a different constraint.

In its own filings, the company lists dependence on revenue from one flagship drug franchise as the first risk it names, ahead of how that drug and its others are covered and reimbursed, how few specialty pharmacies and wholesalers carry its products to patients, and whether it can keep its own sales and distribution operation running. It also discloses that, across its portfolio, it generally has only one or a small number of qualified sources for the raw materials, active ingredients and finished product behind each medicine, with some current products dependent on a single qualified manufacturer.

The company answers to several separate national medicines regulators at once, each able to independently decide whether and how a given therapy may be sold in its market. It is currently in patent litigation with a number of generic-drug makers seeking to enter once exclusivity on its two largest branded products is contested, and separately disputes with the U.S. Medicare agency how one of its dermatology products should be classified for rebate purposes. Its own account also names exposure to trade tension and tariff or export-control action tied to sourcing a key raw material from Chinese suppliers, and describes its foreign revenue and profit as exposed to currency movements because of how global its operations are.